In this interview, we speak to Jenn Edwards from the Abigail Wexner Research Institute (OH, USA) about her research using the primary human epithelial cell models to examine Neisseria gonorrhoeae infections, the potential for vaccination against gonorrhea and a possible host-targeted therapy for this infection.
In this infographic we take a look at the long-acting formulations for HIV prevention and treatment currently in the clinical pipeline – from Phase I to approval.
New research indicates that harnessing RNA sensors could allow human cells to be more attuned to killing tuberculosis, presenting an effective means for controlling the spread of the disease.
Discover more about the two routes phage therapy could take, the standardized drug approach and the personalized medicine approach, and whether either could make it to the clinic.
In this article, we explore the crucial role of shared decision-making in HIV treatment and…
Bacteriophage have been touted as the solution for antibiotic resistant microbes, why are they not being used in mainstream medicine?
Researchers from Gladstone Institutes and their partners at Xyphos Biosciences have demonstrated that a cell-based therapy, convertibleCAR®, appears to reduce the latent HIV reservoir in individuals on antiretroviral therapy.
Researchers have developed nanomeshes as an effective drug-delivery system for antibiotics.
Graham Hatfull speaks about heading up the SEA-PHAGES project and the role this has played in understanding phage diversity and evolution, in addition to commenting on a recent case where a phage cocktail was used to treat a case of Mycobacterium abscessus.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.